Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA022132 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA022132, RRID:AB_1846300
- Product name
- Anti-CD38
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CD38, Gene description: CD38 molecule, Validated applications: ICC, IHC, WB, Uniprot ID: P28907, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.3 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation.
Daratumumab- 225 Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
van den Bosch AMR, van der Poel M, Fransen NL, Vincenten MCJ, Bobeldijk AM, Jongejan A, Engelenburg HJ, Moerland PD, Smolders J, Huitinga I, Hamann J
Nature communications 2024 Feb 23;15(1):1667
Nature communications 2024 Feb 23;15(1):1667
Daratumumab- 225 Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Dawicki W, Allen K, Jiao R, Malo M, Helal M, Berger M, Ludwig D, Dadachova E
OncoImmunology 2019;8(8)
OncoImmunology 2019;8(8)
MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer
Bar I, Theate I, Haussy S, Beniuga G, Carrasco J, Canon J, Delrée P, Merhi A
Journal of Histochemistry & Cytochemistry 2019;68(1):25-32
Journal of Histochemistry & Cytochemistry 2019;68(1):25-32
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein A, Aversa F, Malavasi F, Giuliani N
Oncotarget 2017;8(34):56598-56611
Oncotarget 2017;8(34):56598-56611
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human tonsil and kidney tissues using HPA022132 antibody. Corresponding CD38 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
